Relevant events during the quarter
During the quarter Nanexa carried out a rights issue, yielding SEK 75m in gross proceeds, and announced a business strategy update, focusing its operations on the NEX-22 project, the Novo Nordisk partnership and other prioritised ongoing partner projects. The NEX-20 and NEX-18 projects were put on hold until the financial situation allows. In November, Nanexa announced the signing of an evaluation agreement with a large global pharmaceutical company for the evaluation of Nanexa's PharmaShell technology in the depot formulation of a monoclonal antibody. On the clinical side, Nanexa completed the NEX-20-01 Ph 1 study in October, with results already announced in Aug'23 (see our previous note). In December, Nanexa communicated that the CTA for NEX-22 Ph 1 study in type 2 diabetes (T2D) patients was accepted by the EMA. The Novo Nordisk collaboration and the other partner projects progressed well during the quarter, with the company expecting one or more of the partner projects to materialise into more comprehensive development deals. Currently, Nanexa is answering questions from the authorities' review of the NEX-22 Ph 1 application.
Aktuellt
SENASTE
